Sign inCreate account

Report workspace

Add to folder
NCT04321161COMPLETEDanonymous

Analysis of T Cell Metabolism and Immune Phenotype in Relapsed Acute Myeloid Leukemia Patients Receiving Donor Lymphocyte Infusions and Bicanorm (Sodium Bicarbonate)

Sponsor

Source record

University of Freiburg

Phase

Source record

Early Phase 1

Modality

AI-normalized

small molecule

Target

AI-normalized

T cell metabolism and immune phenotype modulation through sodium bicarbonate treatment in relapsed Acute Myeloid Leukemia (AML) patients receiving donor lymphocyte infusions (DLIs).

Indication / condition

AI-normalized

Acute Myeloid Leukemia, in Relapse

Intervention

Source record

Bicanorm

Source & freshness

Source record

NCT ID

NCT04321161

Original source

ClinicalTrials.gov

Source last updated

Mar 25, 2020

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04321161

Title

Analysis of T Cell Metabolism and Immune Phenotype in Relapsed Acute Myeloid Leukemia Patients Receiving Donor Lymphocyte Infusions and Bicanorm (Sodium Bicarbonate)

Sponsor

University of Freiburg

Status

COMPLETED

Phase

Early Phase 1

Condition raw

Acute Myeloid Leukemia, in Relapse

Condition normalized

Acute Myeloid Leukemia, in Relapse

Modality raw

small molecule

Modality normalized

small molecule

Target raw

T cell metabolism and immune phenotype modulation through sodium bicarbonate treatment in relapsed Acute Myeloid Leukemia (AML) patients receiving donor lymphocyte infusions (DLIs).

Target normalized

T cell metabolism and immune phenotype modulation through sodium bicarbonate treatment in relapsed Acute Myeloid Leukemia (AML) patients receiving donor lymphocyte infusions (DLIs).

Interventions

Bicanorm

Public preview

Source record

The study conducted by the University of Freiburg explores the potential of sodium bicarbonate (Bicanorm) to enhance the efficacy of donor lymphocyte infusions in relapsed AML patients. Given the limited survival benefits associated with DLIs alone, this research could position sodium bicarbonate as a novel adjunct therapy, potentially expanding treatment options in the AML market. The findings may attract interest from biopharmaceutical companies focusing on immunotherapy and metabolic modulation in oncology, highlighting a need for further exploration of metabolic interventions in hematological malignancies. The competitive landscape may shift if sodium bicarbonate demonstrates significant efficacy, prompting further investment and development in this therapeutic area.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Analysis of T Cell Metabolism and Immune Phenotype in Relapsed Acute Myeloid Leukemia Patients Receiving Donor Lymphocyte Infusions and Bicanorm (Sodium Bicarbonate)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 17, 2026

NCT ID

NCT04321161

Status

COMPLETED

Phase

Early Phase 1

Sponsor

University of Freiburg

Executive brief

Investment-Ready Snapshot

The study conducted by the University of Freiburg explores the potential of sodium bicarbonate (Bicanorm) to enhance the efficacy of donor lymphocyte infusions in relapsed AML patients. Given the limited survival benefits associated with DLIs alone, this research could position sodium bicarbonate as a novel adjunct therapy, potentially expanding treatment options in the AML market. The findings may attract interest from biopharmaceutical companies focusing on immunotherapy and metabolic modulation in oncology, highlighting a need for further exploration of metabolic interventions in hematological malignancies. The competitive landscape may shift if sodium bicarbonate demonstrates significant efficacy, prompting further investment and development in this therapeutic area.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 25, 2020
Internal syncJun 17, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04321161

Indication

Acute Myeloid Leukemia, in Relapse

Modality

small molecule

Target

T cell metabolism and immune phenotype modulation through sodium bicarbonate treatment in relapsed Acute Myeloid Leukemia (AML) patients receiving donor lymphocyte infusions (DLIs).

Intervention

Bicanorm

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.